Induced pluripotent stem cells (iPSCs) are being pursued as a source of cells for autologous therapies, many of which will be aimed at aged patients. To explore the impact of age on iPSC quality, we produced iPSCs from blood cells of 16 donors aged 21-100. We find that iPSCs from older donors retain an epigenetic signature of age, which can be reduced through passaging. Clonal expansion via reprogramming also enables the discovery of somatic mutations present in individual donor cells, which are missed by bulk sequencing methods. We show that exomic mutations in iPSCs increase linearly with age, and all iPSC lines analyzed carry at least one gene-disrupting mutation, several of which have been associated with cancer or dysfunction. Unexpectedly, elderly donors (>90 yrs) harbor fewer mutations than predicted, likely due to a contracted blood progenitor pool. These studies establish that donor age is associated with an increased risk of abnormalities in iPSCs and will inform clinical development of reprogramming technology.
l e t t e r s
Induced pluripotent stem cells (iPSCs) are being pursued as a source of cells for autologous therapies, many of which will be aimed at aged patients. To explore the impact of age on iPSC quality, we produced iPSCs from blood cells of 16 donors aged 21-100. We find that iPSCs from older donors retain an epigenetic signature of age, which can be reduced through passaging. Clonal expansion via reprogramming also enables the discovery of somatic mutations present in individual donor cells, which are missed by bulk sequencing methods. We show that exomic mutations in iPSCs increase linearly with age, and all iPSC lines analyzed carry at least one gene-disrupting mutation, several of which have been associated with cancer or dysfunction. Unexpectedly, elderly donors (>90 yrs) harbor fewer mutations than predicted, likely due to a contracted blood progenitor pool. These studies establish that donor age is associated with an increased risk of abnormalities in iPSCs and will inform clinical development of reprogramming technology.
Pluripotent stem cells are being explored as sources of differentiated cells for autologous cell replacement therapies in applications such as spinal cord injury, Parkinson disease, and blindness 1 . Because iPSCs are generated directly from somatic tissues, they can be genetically matched to individuals, reducing the need for immunosuppression. However, this approach also engenders the risk that epigenetic aberrations or mutations in the donor cells will be carried through to iPSCs and their derived tissues, leading to increased tumorigenicity or dysfunction 2, 3 . Indeed, a recent clinical trial of iPSC-derived tissues in Japan was halted after the discovery of potentially tumorigenic mutations in iPSCs 4 . While many well-characterized iPSC lines are derived from youthful tissue, iPSCs intended for autologous therapy will in many cases be produced from the somatic cells of aged patients. Therefore, it is important to understand how age influences the epigenomes and genomes of iPSCs.
Aberrant DNA methylation in iPSCs can alter their differentiation capacity and tumorigenicity 5, 6 . Aberrant DNA methylation can arise from stochastic errors in reprogramming or from a failure to reset patterns of methylation characteristic of donor cells. Thus, iPSCs generated from different cell types often retain some lineagespecific epigenetic signatures, termed epigenetic memory, which may influence their function [7] [8] [9] [10] [11] . Recent studies of aging in somatic tissues have identified a strong epigenetic signature of age based on DNA methylation at CpG sites 12, 13 . This signature is robust enough that DNA methylation patterns at only a small number of sites can accurately predict the chronological age of a donor [12] [13] [14] . Whether reprogramming of elderly donor cells into iPSCs can fully reset this signature has not been examined, although some iPSCs have been reported to have an apparent age of ~−0.7 years 12 , which corresponds to an early post-fertilization age of <1 month gestation. To improve iPSC-based disease modeling and establish guidelines for clinical studies, we must determine the influence of age on epigenetic aberrations in iPSCs.
Mutations present in iPSCs contribute to the tumorigenic risk of iPSC-derived cells. Such mutations can be inherited from the original donor cell or acquired during the process of reprogramming and iPSC expansion. Mutations in iPSCs have been investigated in various ways [15] [16] [17] , with most studies concluding that the majority of mutations are derived from pre-existing somatic mutations in the donor cells while a minority arise during reprogramming, although this may reflect technical difficulties in detecting rare mutations associated with later stages of expansion [18] [19] [20] . The influence of age on the chromosomal somatic mutation load in iPSCs has not been studied experimentally, although it has been inferred that the number of somatic mutations in iPSCs would increase with donor age based on parallel increases in somatic mutation in bulk studies of aging tissues 21 . However, it is becoming apparent that individual cells accumulate rare or unique somatic mutations that are invisible in bulk DNA sequencing studies. Because reprogramming clonally expands the genome of a single cell, iPSCs can capture these rare changes. Thus, reprogramming enables high-resolution detection of rare somatic mutations without the errors and noise inherent to single-cell whole-genome sequencing 19, [22] [23] [24] . Here, we apply this approach to assess the impact of age on rare exomic mutations in blood cells and iPSC lines derived from them, which, to our knowledge, has not been systematically reported for any human lineages.
As age can reduce the efficiency of reprogramming fibroblasts 25 , we elected to reprogram frozen peripheral blood mononuclear cells (PBMCs), which were expanded to eliminate T and B cells and enrich for erythroid progenitor cells, using the Yamanaka approach to episomal reprogramming. We modified the protocol of ref. 26 by optimizing parameters for erythroid progenitor cell expansion, survival after electroporation, and iPSC culture conditions and applied this method to PBMCs from five young (21, 22, 23, 23 , and 29 yrs), five middle-aged (49, 57, 62, 69, and 79 yrs), and six elderly (86, 87, 92, 94, 95, and 100 yrs) individuals ( Fig. 1a and Supplementary Fig. 1c) .
We were able to generate iPSC lines from all donors (at least six lines per donor were banked). Donor age did not significantly influence reprogramming efficiency or iPSC quality based on karyotyping and immunostaining for pluripotency markers TRA-1-60 and SSEA4 (Supplementary Fig. 1 ). Three iPSC lines per donor that were positive for these pluripotency markers, karyotypically normal, and that maintained an undifferentiated morphology during passaging were selected for analyses of DNA methylation and exomic mutations, based on comparisons with the original PBMCs obtained from the donors (Fig. 1a) .
We analyzed DNA methylation via Illumina's Infinium Methylation Assay. As the age of blood cell donors can be predicted based on DNA methylation profiles 12, 13 , we applied the method of ref. 12 and found that we could accurately predict the age of PBMC donors across all age groups (R 2 = 0.96, P-value = 6.4 × 10 −8 ) (Fig. 1b, left panel) . IPSCs exhibit a 'negative' predicted age, similar to that of embryonic stem cells, indicating that reprogramming can reset the epigenetic aging clock 18 . While the genome-wide changes in DNA methylation we observed predicted a negative age for all of our iPSC lines, we also detected a weak residual signature of the donor age (R 2 = 0.38) (Fig. 1b, right panel) . Although some variability in predicted methylation age was observed, the relationship was significant when assessed by a linear mixed effects model accounting for repeated measures per individual donor (P-value = 0.04) (see Online Methods for rationale and description of the model).
During aging, DNA methylation reproducibly increases at some CpG sites and decreases at others. The epigenetic signature of age in blood includes both types of CpG sites, although the former are the best preserved between different tissues and individuals, and these are also thought to be most likely to alter gene expression. To identify the source of the residual age-associated signature in iPSCs, we separately examined the influence of age on methylation levels at these two sets of CpG sites. In the PBMCs, as expected, CpG sites at which methylation has been reported to increase with age exhibit increased DNA methylation in older donors, as shown by plotting the average difference in methylation at each site for the old donors compared to the young donors (Fig. 1c , left: average > 0, average = 0.09). In the iPSCs, these same CpG sites similarly exhibited significantly higher methylation in the older donor cells compared to the younger (Fig. 1c, left: average > 0, average = 0.04) (generalized Friedman rank sum test with replicated data: P-value = 1.3 × 10 −7 ). This could result from a residual age-based program of epigenetic regulation or reflect a broader resistance to demethylation in iPSCs from older donors.
To address this we next examined CpG sites reported previously to decline in methylation with age. We found that, as expected, in PBMCs from our cohort the methylation levels at these sites were lower in the cells from the older donors, plotted as average methylation in older donors minus average in younger donors (Fig. 1c , right: average < 0, average = −0.17) (generalized Friedman rank sum test with replicated data: P-value < 2.2 × 10 −16 ). However, in the iPSCs we derived from these PBMCs the average methylation at each CpG site was significantly higher in the lines derived from older compared to the younger donors (Fig. 1c, left: points average > 0, average = 0.04) (generalized Friedman rank sum test with replicated data: P-value = 1.3 × 10 −7 ) (raw data displayed in Supplementary Dataset 1 and Supplementary Fig. 2 ). These data suggest that the epigenetic signature of age in iPSCs reflects an overall resistance to demethylation during reprogramming at both types of age-associated CpG sites, with a more significant demethylation defect affecting CpG sites whose methylation levels increase with age.
To determine whether this resistance to demethylation during reprogramming of iPSCs from elderly donors is a global phenomenon, we examined DNA methylation at all CpG sites that demethylate significantly during reprogramming (adjusted P-value < 0.05) from PBMCs to iPSCs (defined as CpGs with average methylation (M)-value > 1 (>67% methylation) in PBMCs and an average M-value < −1 (<33% methylation) in iPSCs). We identified 3,896 reprogramming-associated CpG sites that met these criteria. These reprogramming-associated CpG sites were more methylated in iPSCs derived from elderly compared to young individuals, by ~1/3 rd of an s.d. (Supplementary Fig. 3a) , uncovering a small but highly significant global demethylation deficiency in iPSCs from elderly donors (generalized Friedman rank sum test with replicated data, P-value < 2.2 × 10 −16 ). In absolute terms, this corresponds to a ~5% increase in the global methylation levels in iPSCs from older individuals. (3) represents the number of iPSC lines generated from each donor. Black bars and circles indicate samples used for both epigenetic and exomic analyses. Gray lines indicate additional samples used for somatic mutation detection. Right, schematic of the study design. PBMCs from donors were isolated, expanded, and reprogrammed with episomal reprogramming factors. Three iPSC lines per donor were characterized. Unexpanded PBMCs and iPSCs were subjected to exome sequencing and DNA methylation analysis. (b) Donor age is strongly correlated with predicted PBMC age based on PBMC methylation (left panel) (R 2 = 0.96, P-value = 6.4 × 10 −8 ). The predicted age of iPSCs, based on iPSC methylation, is weakly but significantly correlated with donor age (right panel) (R 2 = 0.38, Pearson correlation P-value = 0.04). Each filled circle represents the average predicted age of three iPSCs per individual; the vertical line is standard error. The dashed line is the linear best fit across all individuals. (c) The difference in average methylation levels between elderly and young donors is plotted for CpG sites previously reported to predict age (CpGs that increase in methylation with age on the left; CpGs that decrease in methylation with age on the right). In PBMCs, CpG sites expected to increase in methylation with age (left) show an average increase of methylation in elderly individuals (average of left PBMC plot = 0.09), and CpG sites expected to decrease in methylation with age (right) show an average decrease of methylation in elderly individuals (average of right PBMC plot = −0.17). On the other hand, in iPSCs, both CpG sites expected to increase (left) and decrease (right) in methylation with age show an average increase of methylation in elderly individuals (average of left iPSC plot = 0.04, average of right iPSC plot = 0.01). Visually, there is a clear dissimilarity in the distribution of the methylation differences at age-related CpG sites in PBMCs vs. iPSCs-with age-related CpG sites displaying two different distributions of methylation differences in PBMCs derived from young vs. old donors whereas age-related CpG sites uniformly display increased methylation levels in iPSCs derived from older donors. (d) Heat map displaying the methylation status of all CpG sites found to be significantly resistant to demethylation in older individuals compared to younger donors (blue, high; red, low). iPSCs are ordered by the age of donor. CpG sites are clustered based on their methylation pattern across individuals. Genes are labeled on the right side. (e) DNA methylation profiles for selected iPSC lines were analyzed at early/intermediate and late passages. The methylation status of six CpG sites is plotted with black circle representing M-value for iPSCs at early passage, and red triangle M-value for late passage in selected iPSC lines. The right side shows three CpG sites that correlate with age at early passage, whose methylation is restored after passaging (red linear regression). GJA1 (early passage R 2 (eR 2 ) = 0.44, P-value < 0.0001; late passage R 2 (lR 2 ) = 0.043, P-value = 0.36), WASL (eR 2 = 0.45, P-value < 0.0001; lR 2 = 0.094, P-value = 0.17), ULK4 (eR 2 = 0.53, P-value < 0.0001; lR 2 = 0.042, P-value = 0.37). The left side shows three CpG sites that maintained a significant correlation with age, independent of passage TEAD3 (eR 2 = 0.51 P-value < 0.0001; lR 2 = 0.54 P-value = 0.0001), ZNF 2 17 (eR 2 = 0.45, P-value < 0.0001; (lR 2 ) = 0.45, P-value = 0.0008), ADGRL4 (eR 2 = 0.47, P-value<0.0001; (lR 2 ) = 0.45, P-value = 0.0009). Pearson correlation with two-tailed P-value.
To search for specific genomic regions that might be particularly relevant to understanding the epigenetic variation in iPSCs derived from elderly individuals, we identified CpG sites whose methylation status in iPSCs was significantly associated with donor age (adjusted P-value < 0.05) and whose methylation status displayed a significant and meaningful magnitude of change during reprogramming (an average absolute change in M-value of 1.0, which corresponds to a twofold change in the ratio of methylated to unmethylated CpGs). 109 such CpG sites were identified, including CpG sites that were either defective in demethylation or remethylation during reprogramming (Supplementary Dataset 2 and Supplementary Fig. 4 ). Of these 109 CpG sites, we focused on 34 sites that did not fully demethylate during reprogramming of iPSCs from elderly individuals (Fig. 1d and  Supplementary Fig. 3b) . A number of genes involved in neoplastic processes were identified, for example, TEAD3 (Hippo signaling), ADGRL4 (tumor angiogenesis), and AHRR (tumor suppressor).
Epigenetic signatures in iPSCs, such as cell type 'memory' , have been reduced by extended passaging 27 . As we found that cells from older donors were significantly different from those of younger donors at passage 8, we tested whether these age-associated changes could be eliminated with even more passaging by expanding one line per donor for an additional 20 passages. All but 6 of the 34 persistent changes were restored to levels similar to those in younger donors ( Fig. 1e and Supplementary Fig. 3b) .
To investigate mechanisms underlying the resistance to demethylation, we examined the expression of genes involved in active CpG demethylation and methylation, such as the TET (Ten-Eleven Translocation) enzymes 28 . We found a decrease with age in the expression level of TET1 (R 2 = 0.21, P-value = 0.0015), TET3 (R 2 = 0.46, P-value < 0.0001), and TET2A (R 2 = 0.25, P-value = 0.0005), but not TET2B (R 2 = 0.04, P-value = 0.15) (Supplementary Fig. 3c) . Thus, lower TET family member 
In contrast to epigenetic aberrations, which can be heterogeneous even among clonal cells, somatic mutations in the original donor cell are expected to be uniformly persistent in iPSCs of the same clonal lineage yet diverse across iPSCs from separate clonal lineages due to the presumed stochastic nature of somatic mutation. To determine how donor age influences the number, type, and potential genic impact of mutations in iPSCs, we performed exome sequencing of the PBMC pool along with at least three iPSC lines from the same donor. Each iPSC line is clonally derived from a single peripheral blood cell, in analogous manner to the derivation of the major clone of a tumor from a single normal cell. Therefore, we identified candidate somatic mutations in iPSC lines by comparing them to the bulk original blood sample and applying standard filters used to identify somatic mutations in tumor-normal sequencing studies, that is, filtration of variants detected by the MuTect algorithm (Online Methods). Exomic mutations in the iPSCs derived from somatic exomic mutations in the starting donor cell are present at 50% allelic fraction in the iPSC population. Similarly, mutations induced during reprogramming of the initial donor cell will be present at 50% allelic fraction in the iPSC population. Thus, we restricted our analysis to the somatic mutations most likely to be valid, as opposed to false-positive candidate somatic mutations due to errors in sample preparation, sequencing and/or variant calling, using an allele fraction filter. This approach identified somatic point mutations in all iPSC lines (Supplementary  Dataset 3) . No somatic copy number variations (CNVs) were detected in any line based on read-depth analysis, although this method has limited sensitivity.
Indeed, exomic mutations in iPSCs derived from individual PBMCs increased with donor age, doubling, on average, from 20 to 90 years of age (Fig. 2a) . This correlation was highly significant as assessed by a linear mixed effects model accounting for repeated measures per individual donor (R 2 = 0.38, P-value = 0.0011) (Fig. 2a, dashed  line) . Notably, this relationship was independent of variation in coverage of our iPSC samples (R 2 = 0.002, P-value = 0.38) (Fig. 2c and  Supplementary Dataset 4) . While the allele fraction filter is designed to select for true somatic mutations present in all cells in the iPSC line, it is possible that a small number of reprogramming-associated mutations may be included in these analyses, due to noise in low-coverage regions. However, the linear increase we observed with age shows that we can easily detect an increase in somatic mutations, over any 'noise' imparted by reprogramming-based mutations of lower allele frequency in the population.
Of the 326 somatic coding mutations we identified, 24 were nonsense mutations affecting genes in which loss-of-function mutations are known to impair cellular function or lead to tumorigenesis ( Table 1) . For example, we observed nonsense mutations in MYO7A (c.5899C>T, p.R1967X) and KIRREL3 (c.553C>T, p.R185X). Loss-offunction mutations in one copy of either of these genes cause Usher syndrome, type 1B (OMIM:276903) and autosomal dominant mental retardation (OMIM:607761), respectively. These observations predict an elevated risk for dysfunctional tissues derived from iPSCs of older donors. We also observed a nonsense mutation in TET2 found in somatic myelodysplastic syndromes, and another mutation implicated in cancer (PPM1D). All observed mutations, their coding consequences, and coverage and/or counts in iPSCs vs. donor PBMCs are provided in Supplementary Dataset 3. Despite this, we did not detect any signatures of positive or negative selection of these mutations based on two lines of evidence. First, the proportion of observed missense and nonsense variants to total coding variants did not l e t t e r s significantly deviate from expectations (expected 77% nonsynonymous, observed 75 ± 5%; 95% confidence interval). Second, the fraction of somatic mutations that were coding was also not correlated with age (R 2 = 0.004, P-value = 0.34) (Fig. 2b) . These data also argue that the majority of mutations we identified are of somatic origin. Unexpectedly, iPSCs from extremely elderly donors (~90 years or older) harbored significantly fewer exomic mutations than predicted by the linear increase in somatic mutations observed in the overall population (Fig. 2a, red points) . To determine whether this apparent decline in somatic mutation rate was significant, we compared the goodness of fit for somatic mutations by age for individuals 20-90 years of age (R 2 = 0.63, P-value < 0.0001) (Fig. 2a, dotted line) vs. 20-100 years of age (R 2 = 0.38, P-value = 0.0011) (Fig. 2a, dashed line) . These results confirmed a strong linear relationship between age and somatic mutation count between the ages of 20 to 90, which begins to degrade at extreme age. A linear mixed effects model with the addition of a parameter to indicate individuals over the age of 90 (extreme age indicator), and an interaction term between age and this extreme age indicator, confirmed a statistically significant effect of extreme age on the number of somatic mutations per iPSC line (AIC = 297 vs. 310 for model with and without extreme age parameter respectively, difference in fit P-value = 0.0003, as determined by ANOVA). Thus, iPSC lines produced from donors of extreme age harbored fewer mutations than expected and in some cases, mutational loads were similar to donors one-half to two-thirds of their age.
To investigate the potential mechanism behind this shift in mutations, we examined the nucleotide context of the mutations in each iPSC line. Cell division correlates with the number of mutations in a cell and with the ratio of transition mutations to transversions.
As expected, the ratio of transitions to transversions increases from 20 to ~90 years of age (Fig. 2d) . However, in cells from extremely elderly donors, this ratio begins to revert back to resemble that of young donors (Fig. 2d) . These results suggest that the PBMC progenitor cells in the extremely elderly donors have undergone fewer divisions than would be expected.
One possible explanation for this is that extremely elderly individuals have a restricted pool of hematopoietic stem cells that may be slowly dividing and thus longer lived than other progenitors. To address this question, we reasoned that if extremely elderly individuals have smaller progenitor pools, the proportion of cells in the PBMCs that carry a particular somatic mutation should be higher than in younger donors. Thus, we randomly selected mutations observed in iPSCs and deeply sequenced the corresponding donor PBMC populations in order to determine the number of cells that were likely to carry these mutations, in other words, the level of somatic mosaicism at these sites. As predicted, we observed a strong linear relationship between donor age and the degree of detectable somatic mosaicism for these mutations (R 2 = 0.66, P-value = 0.028) (Fig. 2e and Supplementary Dataset 5) . This result is consistent with models in which PBMCs from older individuals derive from a restricted and/or genomically protected hematopoietic progenitor pool that has undergone fewer cell divisions than progenitors supplying PBMCs to middle-aged donors (Fig. 2f) .
Together, our results demonstrate that donor age poses a risk to the safety of iPSCs because the likelihood of aberrations inherited from the donor blood cells increases with age. We show that the previously described epigenetic signature of advanced biological age is evident in blood cells derived from our donors and that traces of this signature persist in iPSCs from older donors, leading to an epigenetic signature of age in the iPSCs. This signature correlated with decreased expression of several TET family genes and also affected genes linked to cancer, suggesting that it could influence iPSC safety and function. However, we also show that extended passaging can erase most of the residual aberrant DNA methylation, indicating that improved reprogramming techniques or increased monitoring of methylation could improve iPSC safety and quality.
In contrast, improved reprogramming techniques cannot reduce the burden of age-associated somatic mutations that iPSCs inherit from donor cells. Encouragingly, we saw no evidence for positive selection of somatic mutations in iPSCs and observed a large degree of heterogeneity in the somatic mutations identified between lines derived from the same individual, suggesting that genome sequencing would be an effective means to screen and select iPSC lines least prone to dysfunction. Computational means to assess the pathogenicity of somatic mutations will be important to identify mutations that promote tumorigenicity and dysfunction of the derived tissue. Given our source of donor material (PBMCs), our study could not differentiate between inborn germline mutations and subsequent mutations that underwent positive selection and rose to high abundance, as has been observed in elderly individuals 29, 30 . To avoid this possibility, we suggest that, especially in elderly individuals, a second tissue should be used as a reference for germline mutations.
Somatic mosaicism may increase with age not only through selection of growth-promoting mutations but also through contraction of the cellular population available for reprogramming at advanced age. This has been difficult to assess because bulk sequencing studies cannot identify rare mutations, and single-cell whole-genome sequencing suffers from a high degree of noise due to amplification and loss of individual DNA molecules. Our results show that amplification of the genomes of blood cells from extremely elderly individuals by reprogramming facilitates assessment of the burden of rare mutations. We observed an overall l e t t e r s decrease in the number of somatic mutations per line from donors older than ~90. Our observation of the reversion of transition as compared to transversion rates in extremely elderly individuals, and the ageassociated increase in allelic frequency of rare somatic mutations in the overall PBMC population, suggests that a reduction in the progenitor cell population for PBMCs may explain the overall decline in the number of somatic mutations observed in extremely elderly individuals-a phenomena previously observed in a single supercentenarian with only two hematopoietic lineages remaining 30 . We cannot definitively differentiate between this possibility and some enhancement of DNA repair in long-lived individuals. However, if such 'less mutated' donor cells are present also in donors <90 years old, it may be useful to identify markers for these cells or use genome sequencing to identify iPSCs derived from them for clinical use. Our systematic study of the effect of age and advanced age on the genetic and epigenetic dynamics of iPSCs relied on our efficient technique for reprogramming PBMCs of elderly individuals. Biomaterials from elderly individuals are not typically used during the development of techniques for cell therapies, although these individuals are most likely to receive clinical benefit. This work highlights some considerations for clinical translation of reprogramming techniques to the clinic and offers an approach for investigating the impact of age on the epigenetic and genetic features of iPSCs and somatic cells.
MeThodS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. removed. Additional filters were applied to eliminate false-positive somatic variant calls, somatic variants must have: 1) alternate allele mapping quality greater than 30, 2) no overlapping indels, 3) at least 50× coverage in the normal PBMC sample, and 4) 30-60% population fraction in the iPSC sample. The final filter was necessary to remove systematic errors in variant calling evident by recurrent "mutations" appearing in multiple lines across individuals or observed in somatically re-arranged antibody genes.
Methylation analysis. PBMC and iPSC methylation was determined via the Infinium Human Methylation 450k array (Illumina Inc., San Diego, CA). Methylation analysis was conducted on the 21, 22, 23 (1), 23 (2), 29, 49, 57, 62, 86, 87, and 100 year-old individuals and processed via a pipeline based on Touleimat and Tost 2012 (ref. 37) . Probes known to overlap with known single-nucleotide polymorphisms (SNP) or CNV sites in any 1000 Genomes population, known to have non-optimal binding, or mapping to sex chromosomes or multiple sites in the genome were removed. Methylation values were determined using the lumi R package 38 , where color bias was adjusted via simple shift and scaling normalization, background adjusted separately per color, and cross-array normalization was performed using via simple shift and scaling normalization. Resultant M-values values were smoothed with a 250-bp window size 39 . The mean overall signal in young iPSC samples was −0.32 vs. −0.34 in iPSC samples from elderly individuals. This difference is non-significant, thus no technical bias exists and, if anything, the trend in bias is toward decreased methylation in iPSCs from elderly individuals-i.e., in the opposite direction of the demethylation defects we observe. Biological age was determined using R code produced by Horvath 18 .
Statistical analysis. Linear mixed effects models were used to account for repeated measures (i.e., multiple iPSC lines) per donor. In analyses assessing the relationship between donor age on genomic outcomes (predicted iPSC and number of somatic mutations), the age of the donor acts as the fixed effect and the source donor acts as the random effect (e.g., the subject-specific effect). Regression is performed via the generic lme function from the nlme R package-with random intercepts and normality assumed and homogenous variance not assumed. Appropriateness of the normality assumption was confirmed by the distribution of observed residuals.
Differential methylation analysis was conducted similarly using the limma R package with the source donor encoded as a blocking factor and the random effect fit for this blocking factor via the intra-subject correlation between iPSC samples derived from the same source donor 40 . An empirical Bayes adjustment is applied to moderate the resultant statistics, and the Benjamini & Hochberg method is applied for multiple testing correction. All reported P-values reflect the corrected values. Statistical analysis for Figure 1e and Supplementary  Figure 3b ,c was performed using GraphPad Prism software.
